The National Health Authority has begun rolling out India's national medical terminology set and a companion drug registry, according to reporting by Healthcare Asia Magazine. For hospital owners, MDs and administrators, this is less a clinical story and more an IT-and-operations one: every HIS, EMR and pseudo-pharmacy module in the country will eventually have to speak the same coded language, or risk breaking ABDM handshakes, TPA claims and audit trails.
The terminology release is an India-localised code set derived from international standards like SNOMED CT and LOINC, adapted to the diagnoses, procedures and lab tests that Indian doctors actually record. The drug registry is a parallel catalogue of medicines — brand, generic, strength, form, manufacturer — meant to become the single reference every prescription, e-pharmacy transaction and discharge summary points to. Both are being pushed under the ABDM umbrella, which means Health IDs, Health Information Providers and Health Information Users will all be nudged towards using them.
For a 200-bed hospital, this is the difference between a discharge summary that reads "T2DM on metformin 500 BD" and one that carries structseed codes a downstream insurer, second-opinion consultant or ABDM locker can actually parse. The clinical text does not go away; the codes get added behind it. But somebody has to do the mapping, and that somebody is your HIS vendor plus your medical records team.
TPAs and PMJAY-empanelled hospitals already see rejections and query cycles that eat 15-30 days of receivables. A standardised terminology reduces one category of those rejections — the ones caused by ambiguous diagnosis descriptions or non-standard drug names. When the payer's system can code-match your discharge summary, the query rate drops. When it cannot, your billing team writes justification notes and your DSO stretches into next quarter.
The drug registry has a second-order effect on pharmacy margins. Substitution rules, generic-equivalence checks and expiry-linked stock rotation all become easier when every SKU on your shelf carries a registry ID. Store managers stop guessing whether "Pan 40" and "Pantoprazole 40mg" are the same line item. Auditors stop asking why the same molecule appears under four different names in the inventory.
Ask your HIS provider three concrete questions before the next quarterly review. One, what is their roadmap for mapping the internal problem list and diagnosis master to the NHA terminology, and by when. Two, does their pharmacy module accept the drug registry ID as a native field or as a bolt-on tag — the former will scale, the latter will not. Three, when the registry version updates every few months, how do their existing customers receive the delta — is it a background sync or a manual re-import.
Vendors who cannot answer these questions today are not necessarily bad partners, but they need to be on notice. The gap between vendors who engineered for ABDM from the start and vendors who are catching up will widen sharply over the next two years. The buying decision made in 2026 will show up as either a smooth 2027 or a painful one.
Before the terminology is enforced at claims level — which will happen, even if the exact quarter is unclear — three internal projects are worth starting now. First, run a diagnosis-master cleanup: dedupe the eight to ten variants of "hypertension" that the EMR has accumulated, and pick the one that will be the registry-linked canonical entry. Second, run a drug-master reconciliation with pharmacy: retire dead SKUs, flag high-turnover items for early registry mapping, and confirm supplier-side compatibility. Third, brief the medical records officer on what "structured discharge summary" will mean operationally — because the workflow change lands on that desk first.
None of this is glamorous work. It is the healthcare-IT equivalent of GST migration in 2017 — hospitals that did the master-data cleanup early paid less pain later. The ones that treated it as an IT-department problem hit reconciliation issues for months.
Chains running three or more outlets on separate HIS instances, or on the same HIS but with independent masters, will have to do the terminology mapping outlet by outlet unless the vendor supports a central master with local synchronisation. Diagnostic chains face the same at their branch labs — every centre with its own test master will need to map to the terminology and, for pharmacy-linked panels, the drug registry too. A chain that has already consolidated onto a single tenant with centrally-managed masters will finish this in weeks. A chain that has not will spend a year on it, and the delta will show up in TPA cashflow long before it shows up in audit reports.
HODO Healzapp is built around ABDM-compliant EMR, so the plumbing for terminology-linked problem lists and structured discharge summaries is already in place — the mapping exercise becomes a configuration project, not a re-platform. The Pharmacy module is designed to hold registry-style drug IDs alongside brand and generic fields, so the drug registry rollout is a master-data update rather than a schema change. And the EMR (AI-condensed history) feature normalises free-text clinical notes into structured summaries, which shortens the manual mapping load on medical records teams during the transition window.
See how Healzapp handles this — book a 30-min demo.
See how Healzapp, Labzapp and EReazy fit your speciality in a free 30-minute demo.
Book a Free Demo